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Since STAT3 activation is involved in tumor progression and
metastasis, we investigated the effect of GSNO in cell culture and
mouse xenograft model of head and neck squamous cell carci-
noma (HNSCC). GSNO treatment of HNSCCN cell lines reversibly
decreases the activation (phosphorylation) of STAT3 in a concen-
tration dependent manner. The reduced STAT3/NF-kB activity by
GSNO correlated with decreased cell proliferation and increased
apoptosis of HNSCC cells. In HNSCC mouse xenograft model, the
tumor growth was reduced by systemic treatment with GSNO and
was further reduced when the treatment combined with radiation
and cisplatin. Accordingly, GSNO treatment also resulted in
decreased levels of pSTAT3 and tumor growth regulators (ie. cyclin
D2, VEGF and Bcl-2) in tumor tissue. In summary, these ﬁndings
have implications for the development of new therapeutics
targeting of STAT3 for treating diseases associated with inﬂam-
matory/immune responses and abnormal cell proliferation, includ-
ing cancer.
http://dx.doi.org/10.1016/j.redox.2015.09.021
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The acquired ability of tumour cells to avoid destruction by
immune effector mechanisms (immune escape) is important for
malignant progression. Also associated with malignant progression is
tumour hypoxia, which induces aggressive phenotypes such as inva-
sion, metastasis and drug resistance in cancer cells. Our studies
revealed that hypoxia contributes to escape from innate immunity
by increasing tumour cell expression of the metalloproteinase
ADAM10 in a manner dependent on accumulation of the alpha
subunit of the transcription factor hypoxia-inducible factor-1 (HIF-
1α). Increased ADAM10 expression leads to shedding of the NK
cell-activating ligand, MICA, from the surface of tumour cells, thereby
resulting in resistance to NK cell-mediated lysis. Our more recent
studies demonstrated that hypoxia, also via HIF-1α accumulation,
increases the expression of the inhibitory co-stimulatory ligand PD-
L1 on tumour cells. Elevated PD-L1 expression leads to escape from
adaptive immunity via increased apoptosis of CD8+ cytotoxic T
lymphocytes. Accumulating evidence indicates that hypoxia-induced
acquisition of malignant phenotypes, including immune escape, is in
part due to impaired nitric oxide (NO)-mediated activation of cGMP
signalling and that restoration of cGMP signalling prevents such
hypoxic responses. We have shown that NO/cGMP signalling inhibits
hypoxia-induced malignant phenotypes likely in part by interfering
with HIF-1α accumulation via a mechanism involving calpain. These
ﬁndings indicate that activation of NO/cGMP signalling may have
useful applications in cancer therapy.
http://dx.doi.org/10.1016/j.redox.2015.09.022
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We previously reported that oncogenic KRAS activation of the
PI3K/AKT pathway stimulates the remaining wild-type HRAS and
NRAS proteins in a manner dependent upon both eNOS expression
and C118 in HRAS and NRAS, which promoted tumor growth.
Interestingly however, we recently found that loss of wild-type HRAS,
NRAS, and even more potently, loss of both of these genes actually
enhanced oncogenic KRAS-driven early tumorigenesis. Taken together,
these results indicate that wild-type RAS proteins are tumor suppres-
sing early in tumorigenesis, but tumor promoting in more malignant
settings. Knock-in of a C118S mutation into an endogenous wild-type
RAS gene did not, however, hamper oncogenic KRAS-driven tumor
initiation. As such, redox-dependent reactions with C118 of wild-type
RAS proteins are unlikely to be responsible for the tumor suppressive
role of wild-type RAS proteins. This suggests that the redox-dependent
reactions with C118 of wild-type RAS proteins are more important in
more malignant settings. Given this, it stands to reason that inhibiting
redox-dependent reactions like S-nitrosylation of wild-type RAS
proteins may be more effective in established cancer settings. Indeed,
we ﬁnd that in three different models of KRAS-driven cancers-skin,
pancreatic and lung- the general NOS inhibitor L-NAME reduced tumor
burden and/or extended the lifespan of mice. Since oncogenic RAS has
so far proven refractory to pharmacologic inhibition, targeting NOS
activity may be an actionable approach to inhibiting RAS signaling for
the treatment of a broad spectrum of cancers.
http://dx.doi.org/10.1016/j.redox.2015.09.023
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The expansion of pluripotent cells (ESCs and iPSCs) under condi-
tions that maintain their pluripotency is necessary to implement a cell
therapy program. Previously, we have described that low nitric oxide
(NO) donor diethylenetriamine/nitric oxide adduct (DETA-NO) added
to the culture medium, promote the expansion of these cell types. The
molecular mechanisms are not yet known. We present evidences that
ESC and iPSCs in normoxia in presence of low NO triggers a similar
response to hypoxia, thus maintaining the pluripotency. We have
studied the stability of HIF-1α (Hypoxia Inducible Factor) in presence
of low NO. Because of the close relationship between hypoxia,
metabolism, mitochondrial function and pluripotency we have ana-
lyzed by q RT-PCR the expression of genes involved in the glucose
metabolism such as: HK2, LDHA and PDK1; besides other HIF-1α
target gene. We further analyzed the expression of genes involved in
mitochondrial biogenesis such as PGC1α, TFAM and NRF1 andwe have
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